Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Farolfi

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Frontiers in Oncology|August 9, 2021
Melphalan as a Promising Treatment for BRCA-Related Ovarian CarcinomaVincenza Conteduca, Emanuela Scarpi, Alberto Farolfi, et al.
Expert Opinion on Pharmacotherapy|August 14, 2020
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancerAmelia Altavilla, Chiara Casadei, Cristian Lolli, et al.
Heart (British Cardiac Society)|January 26, 2013
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factorsAlberto Farolfi, Elisabetta Melegari, Michele Aquilina, et al.
Frontiers in Oncology|October 19, 2020
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell TumorsGiuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2015
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancerAlberto Farolfi, Emanuela Scarpi, Andrea Rocca, et al.
Scientific Reports|October 20, 2018
Plasma androgen receptor and serum chromogranin A in advanced prostate cancerVincenza Conteduca, Emanuela Scarpi, Samanta Salvi, et al.
Frontiers in Endocrinology|April 14, 2018
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?Sara Bravaccini, Sara Ravaioli, Dino Amadori, et al.
Frontiers in Oncology|September 4, 2023
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patientsAlberto Farolfi, Elisabetta Petracci, Giorgia Gurioli, et al.
BMC Cancer|December 21, 2018
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerVincenza Conteduca, Giorgia Gurioli, Lorena Rossi, et al.
Cancers|November 7, 2019
Plasma Androgen Receptor in Prostate CancerVincenza Conteduca, Giorgia Gurioli, Nicole Brighi, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Frontiers in Oncology|August 9, 2021
Melphalan as a Promising Treatment for BRCA-Related Ovarian CarcinomaVincenza Conteduca, Emanuela Scarpi, Alberto Farolfi, et al.
Expert Opinion on Pharmacotherapy|August 14, 2020
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancerAmelia Altavilla, Chiara Casadei, Cristian Lolli, et al.
Heart (British Cardiac Society)|January 26, 2013
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factorsAlberto Farolfi, Elisabetta Melegari, Michele Aquilina, et al.
Frontiers in Oncology|October 19, 2020
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell TumorsGiuseppe Schepisi, Vincenza Conteduca, Chiara Casadei, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2015
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancerAlberto Farolfi, Emanuela Scarpi, Andrea Rocca, et al.
Scientific Reports|October 20, 2018
Plasma androgen receptor and serum chromogranin A in advanced prostate cancerVincenza Conteduca, Emanuela Scarpi, Samanta Salvi, et al.
Frontiers in Endocrinology|April 14, 2018
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?Sara Bravaccini, Sara Ravaioli, Dino Amadori, et al.
Frontiers in Oncology|September 4, 2023
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patientsAlberto Farolfi, Elisabetta Petracci, Giorgia Gurioli, et al.
BMC Cancer|December 21, 2018
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancerVincenza Conteduca, Giorgia Gurioli, Lorena Rossi, et al.
Cancers|November 7, 2019
Plasma Androgen Receptor in Prostate CancerVincenza Conteduca, Giorgia Gurioli, Nicole Brighi, et al.
Pageof 7